InnoCan Pharma Corporation (CSE:INNO)
4.000
-1.000 (-20.00%)
May 21, 2026, 12:37 PM EST
InnoCan Pharma Earnings Call Transcripts
Fiscal Year 2025
-
Three-pillar strategy targets chronic pain, veterinary pain, and wellness, with LPT/CBD advancing toward first-in-human trials and strong preclinical results. Despite revenue decline, gross margins remain above 90%, and the wellness segment shows resilient profitability.